Eevia Health Plc Interim Report Q3 - 2023
Significant events during the third quarter of 2023:Net sales1 decreased by 20% from KEUR 1 148 in Q3-22 to KEUR 917 in Q3-23. Compared to the second quarter this year, Net sales decreased by 54%, from KEUR 1 985. The gross profit in Q3-23 landed at KEUR 347, a decrease of 52% from KEUR 725 in Q3-22 and down 70% from KEUR 1 352 in Q2-23. The gross margin2 was 38% in Q3-23, down from 63% in Q3-22 and 68% in Q2-23. The decrease since the previous quarters is due to a changing product mix. There was no effect on gross margin from side-stream products in Q3-23. EBITDA in Q3-23 was KEUR 2